In August, DCEG scientists participated in the 29th International Papillomavirus Conference in Seattle, Washington. The meeting highlighted basic, clinical, and public health science topics ranging from molecular virology to novel cancer screening and treatment strategies to global public health.
Aimée R. Kreimer, Ph.D., presented a plenary talk “Oral HPV natural history and its progression to oropharyngeal cancer.”
Other DCEG staff members took part in a wide array of activities:
Anil Chaturvedi, Ph.D., co-chaired a session on Clinical Sciences: Cervix 2, and presented on “Oral HPV infection among men and women in the United States, NHANES 2009-2012” at a session on Clinical Sciences: Head & Neck.
Julia Gage, Ph.D., co-chaired a session on Clinical Sciences/Clinical Screening, and presented “Potential safety of primary HPV testing: Evidence from 1 million women undergoing HPV and Pap testing in routine cervical cancer screening since 2003" at a session on Clinical Sciences: Screening and Guidelines.
Allan Hildesheim, Ph.D., co-chaired a session on Public Health Sciences: Vaccines 1 and presented “HLA associations in non-HPV viral cancers" at a satellite symposium on HPV-related Cancer Genetics. He also presented a poster “Impact of HPV 16/18 vaccination on prevalent infections and on recurrence after excisional treatment".
Hormudz Katki, Ph.D., presented “Using cervical precancer/cancer risks based on 1 million women to develop the 2012 US screening and management guidelines incorporating HPV testing” at a session on Clinical Sciences: Screening and Guidelines.
Krystle Lang Kuhs, Ph.D., presented “Reduced prevalence of vulvar HPV16/18 infection among women who received the bivalent vaccine: A nested analysis within the Costa Rica Vaccine Trial” at a session on Public Health Sciences: Vaccines 2.
Lisa Mirabello, Ph.D., presented “Novel HPV 16 genetic polymorphisms are associated with an increased risk of CIN 3+ in women infected with European lineage (A) variants” at a session on Public Health Sciences: Epidemiology.
Hilary Robbins, M.S.P.H., presented a poster "Immunogenicity assessment of HPV 16/18 vaccine using glutathione S-transferase multiplex serology".
Mahboobeh Safaeian, Ph.D., presented “HPV16 antibody avidity following one and two doses of HPV 16/18 vaccine: Results from the Costa Rica HPV 16/18 Vaccine Trial (CVT)" at a session on Public Health Sciences: Vaccines 1, and “Immunoepidemiologic correlates of vaccination with fewer than three HPV vaccine doses “ at a satellite symposium on Incomplete Vaccination Among Target Age Adolescents: Need for Completing Series? She also gave the overview of session objectives and introduction of speakers at the satellite symposium HPV-related Cancer Genetics.
Vikrant Sahasrabuddhe, Ph.D., presented “Improving cervical cancer prevention among HIV+ women using HPV-based biomarker assays: design and initial results from a multicentric study in India" at a session on Clinical Sciences: Cervix 1, and presented a poster “Evaluation of two urine-based HPV assays in comparison to cervical HPV detection and high-grade CIN among women attending a colposcopy clinic".
Mark Schiffman, M.D., M.P.H., co-chaired a session on Public Health Sciences: Screening – Strategy.
Nicolas Wentzensen, M.D., presented “Evaluation of P16/KI-67 cytology for detection of cervical precancers in HPV-vaccinated women” at a session on Public Health Sciences: Clinical and Screening.